JMP Securities initiated coverage of Vigil Neuroscience with an Outperform rating and $23 price target. Vigil is a neuroscience-focused biotech company with lead programs targeting microglial receptor protein TREM2, the analyst tells investors in a research note. The firm says interim results from the VGL101 Phase 2 trial are anticipated in Q4 and represent the key near-term, value-driving milestone.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VIGL:
- Vigil Neuroscience announces first patient dosed in Phase 1 trial of VG-3927
- Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
- Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
- Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
- Vigil Neuroscience receives positive opinion from EMA on ODD for VGL101
